Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Inhibitors & Agonists-Metabolic Enzyme/Protease-Angiotensin-converting Enzyme (ACE)

Request The Product List ofAngiotensin-converting Enzyme (ACE) Angiotensin-converting Enzyme (ACE)

Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure.

Cat. No. Product Name CAS No. Information
H9000

Vicenin-1

 		35927-38-9

Vicenin 1 is a C-glycosylflavone isolated from the aerial parts of Desmodium styracifolium, has an inhibitory effect on angiotensin-converting enzyme (ACE)(IC50=52.50 μM).
H4985

Lisinopril

 		76547-98-3

A angiotensin-converting enzyme (ACE) inhibitor for treatment of hypertension, heart failure, and after heart attacks.
H4984

Ilepatril

 		669764-02-7

A potent, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 0.053 and 5.0 nM, respectively; displays good in vitro selectivity over a large variety of targets; restores endothelial function by increasing the ratio of NO to O2- concentration and bioavailability of NO, prevents albuminuria and reduces the incidence and severity of glomerulosclerosis and tubulointerstitial damage in vivo.
H4983

Gemopatrilat

 		160135-92-2

A potent, orally available, dual ACE-neutral endopeptidase (vasopeptidase) inhibitor with IC50 of 12 and 63 nM, respectively; causes prolonged inhibition of circulating and renal ACE and renal NEP after a single oral dose in atherogenic diet rabbits.
H4988

Omapatrilat

 		167305-00-2

A potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively; shows moderate activity against APP, and low activity against ECE1; causes significant inhibition of plasma ACE and increases plasma renin activity, reduces blood pressure in spontaneously hypertensive rats; orally active.
H4987

MLN-4760

 		305335-31-3

MLN-4760 (MLN4760) is a potent, selective inhibitor of angiotensin-converting enzyme (ACE)-related carboxypeptidase ACE2 with IC50 of 0.44 nM (hACE2); displays >5,000-fold selectivity over related enzymes including human testicular ACE (IC50>100 uM) and bovine carboxypeptidase A (IC50=27 uM); exacerbated the Ang II-dependent formation of ROS and abolished the generation of Ang-(1-7) from Ang II; exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats.
H4986

Lisinopril dihydrate

 		83915-83-7

A angiotensin-converting enzyme (ACE) inhibitor for treatment of hypertension, heart failure, and after heart attacks.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1